02268.HK
WuXi XDC Cayman Inc
HKSE · Healthcare · Medical - Diagnostics & Research · CN
HKD 67.90
−1.95%Year over year
Reported trailing growth
- Revenue
- +35.5%
- EBITDA
- +49.0%
- EBIT
- +47.5%
- EPS
- +22.0%
- Free cash flow
- +1347.8%
- Operating cash flow
- +62.2%
Forward estimates
Based on analyst estimates
- Revenue
- +134.0%
- EBITDA
- +211.8%
- EPS
- +185.3%
Three-year CAGR
- Revenue
- +81.7%
- EBITDA
- +124.3%
- EBIT
- +134.4%
- Net income
- +111.8%
- EPS
- +110.9%
- Free cash flow
- +132.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026